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The results of quantitative footprinting studies involving the antiviral agent netropsin and a
DNA-cleaving cationic metalloporphyrin complex are presented. An analysis of the footprinting autoradiographic spot intensities using a model previously applied to footprinting studies involving the enzyme
DNase I [Ward, B., Rehfuss, R., Goodisman, J., & Dabrowiak, J. C. (1988) Biochemistry 27, 1198-12051
led to very low values for netropsin binding constants on a restriction fragment from pBR-322 DNA. In
this work, we show that, because the porphyrin binds with high specificity to DNA, it does not report site
loading information in the same manner as does DNase I. We elucidate a model involving binding equilibria
for individual sites and include competitive binding of drug and porphyrin for the same site. The free porphyrin
and free drug concentrations are determined by binding equilibria with the carrier (calf thymus DNA) which
is present in excess and acts as a buffer for both. Given free porphyrin and free netropsin concentrations
for each total drug concentration in a series of footprinting experiments, one can calculate autoradiographic
spot intensities in terms of the binding constants of netropsin to the various sites on the 139 base pair restriction
fragment. The best values of these binding constants are determined by minimizing the sum of the squared
differences between calculated and experimental footprinting autoradiographic spot intensities. Although
the determined netropsin binding constants are insensitive to the value assumed for the porphyrin binding
constant toward its highest affinity sites, the best mean-square deviation between observed and calculated
values, D, depends on the choice of (average) drug binding constant to carrier DNA, Kd. Since D as a function
of Kd passes through a clear minimum, we were able to determine this parameter as well. The study
demonstrates that the specificity of probe binding to D N A is an important factor influencing the reporting
of site occupancy by drug in the quantitative footprinting experiment.
ABSTRACT:

In

the footprinting experiment, a ligand is allowed to bind
to a DNA molecule before exposure of the ligand-DNA
complex to a cleavage agent. From the way in which the
amount of a particular DNA oligomer produced in the digest
changes with the amount of ligand added, one can determine
whether ligand binds at a specific site on the DNA lattice. In
a quantitative footprinting experiment, one attempts to extract
values for the equilibrium binding constants of the ligand by
analyzing the concentrations of DNA oligomers as a function
of ligand concentration and sequence.
The most commonly used footprinting agent or probe is the
DNA hydrolytic enzyme DNase I. Ackers and co-workers
(Brenowitz et al., 1986a,b; Senear et al., 1986; Carey, 1988)
have recently reported that this enzyme yields valid individual-site isotherms for protein-DNA interactions. While the
extension of quantitative footprinting techniques to drugs and
other small ligands appears straightforward, the low binding
specificities and reduced affinities of these agents complicate
the extraction of binding constants from footprinting data.
In recent quantitative studies involving the antiviral agent
netropsin, a 139 base pair restriction fragment of pBR-322
DNA, and DNase I, we demonstrated that it is possible to
obtain drug binding constants as a function of sequence from
footprinting data (Ward et al., 1988a). After addressing
DNase I redistribution effects due to drug binding (Ward et
al., 1988b) and site exclusions due to overlapping binding sites
on DNA, we analyzed the autoradiographic data associated
with binding events as well as enhancements, obtaining values
‘This work was supported by a grant from the American Cancer
Society, NP-68 1.

for a number of affinity constants for netropsin. The results
indicated that, although the high-affinity drug sites are all of
type (AeT),, the presence of the sequence 5’-TA-3’, which
produces a distortion within the site, (Chuprina, 1987) discourages netropsin binding to DNA.
Since quantitative footprinting analysis is certain to have
a major role in the design and synthesis of new generations
of sequence-specific drugs (Hurley & Boyd, 1987), it is important to more clearly define the scope and limitations of the
new method. In this work, we examine how the cleavage
characteristics of the probe affect reporting of valid binding
information in the footprinting experiment. We carried out
quantitative footprinting studies of netropsin bound to a 139
base pair restriction fragment, using, instead of DNase I as
a cleaving agent, the DNA-cleaving cationic manganeseporphyrin complex MnT4MPyP. The different cleavage
properties associated with the porphyrin lead to substantial
differences from the previous work. Unlike DNase I, which
cleaves at many sites on DNA, MnT4MPyP prefers to cleave
at trinucleotide sequences containing only the bases adenine
and thymine, Le., (AaT), (Ward et al., 1986, 1987). In addition to altered specificity, DNase I and MnT4MPyP exhibit
different binding and cleavage mechanisms. While the enzyme
binds to a well-formed minor groove (Suck et al., 1988), the
metal complex interacts in what appears to be a melted or
partially melted region of DNA (Raner et al., 1988, 1989;
Geacintov et al., 1987). Activation of the porphyrin is believed
to proceed through a high-valent oxo intermediate which attacks the deoxyribose group, ultimately producing a strand
break in the polymer (Ward et al., 1986; Bortolini et al., 1986;
Groves & Nemo, 1983a,b). This behavior contrasts with that
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The numbering system used is the genomic numbering system
of pBR-322 DNA (Maniatis et al., 1982). Experimental
protocols for the footprinting experiments and the synthesis
of MnT4MPyP were as previously described (Ward et al.,
1987; Raner et al., 1988).
Briefly, all reactions were carried out in 50 mM Tris-HCl
buffer at pH 7.5 for 20 min at 37 OC. The final DNA concentration in base pairs in each of the 14 reactions was 194
pM (193 pM sonicated calf thymus DNA and 1 pM labeled
fragment). Two control reactions were carried out in the
absence of netropsin by equilibrating the porphyrin and DNA
for 30 min in a total volume of 6 p L followed by the addition
of 2 pL of a 4 mM solution of freshly prepared oxone, KHS05,
in buffer. The 12 reactions involving netropsin were carried
out in an identical manner by incubating the drug and the
porphyrin with DNA for 30 min in 6 p L followed by the
addition of 2 p L of the activating agent. The final total
concentration of porphyrin in all experiments was 1.3 pM.
Final total concentrations of netropsin employed in the various
experiments were as follows (pM): 1.09, 1 SO, 2.08,2.88,3.99,
5.52,7.64, 10.6, 14.6,20.3,27.0, and 38.8. After termination
of the digest, the reaction products were separated in a 12%
denaturing polyacrylamide gel with a thermostated field
gradient electrophoresis device developed in-house. The resulting autoradiogram, Figure 1, was scanned with a linear
scanning microdensitometer to yield band cross-sectional areas
(ai = band area for site i) directly proportional to oligonucleotide concentrations (Dabrowiak et al., 1986). Single
nucleotide resolution was obtained at position 45-1 10 with
lower resolution at positions above 110. Establishment of
sequence was as earlier described (Lown et al., 1986).
Careful inspection of the ladder of bands produced by
porphyrin cleavage relative to those produced by DNase I
cleavage revealed that the shortest porphyrin oligomer, a 13mer, migrated more slowly, by 1 nucleotide, than the corresponding DNase I oligomer. The longer oligomers from both
sources showed a 1 :1 correspondence in electrophoretic mobility. Since the ladder of porphyrin-produced bands is not
complete, as is that produced by DNase I, the lack of correspondence of the shorter oligomers went unnoticed in earlier
work involving the porphyrin (Ward et al., 1986,1987), leading
to an error in sequence assignment for the porphyrin cleavage
in the region 45-5 1 . The corrected porphyrin cleavage sites,
its binding sites, and those of the drug are shown on the sequence of the fragment in Figure 2.
The 5'-terminal sequence 5'-ATTAAA-3' at positions 38-33
would be expected to bind both drug and porphyrin. However,
due to their short lengths, these oligomers migrated from the
end of the gel into the buffer well, and thus no direct infor-

Photograph of autoradiographic data of the netropsin139-mer interaction as probed with MnT4MPyP/oxone. Lane 1 , no
porphyrin control; lanes 2 and 17, DNase I cleavage of the 139-mer
in the absence of netropsin; lanes 4-15, cleavage by MnT4MPyP/
oxone in the presence of various concentrations of netropsin. The drug
concentrations used (lane 4 highest, lane 15 lowest) can be found under
Materials and Methods.
FIGURE 1:

of DNase I, which, through a calcium-dependent reaction,
catalyzes the hydrolysis of the phosphodiester backbone of
DNA (Suck et al., 1988).
MATERIALS
AND METHODS
The 139 base pair HindIII/NciI restriction fragment obtained from pBR-322 DNA was 3'end labeled at position 33
with [w3*P]ATPand reverse transcriptase (Lown et al., 1986).
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FIGURE 2: Sequence of the HindllI/IVciI139 base pair restriction fragment of pBR-322 DNA. The asterisk denotes the position of the radiolabel.
Porphyrin cleavage site (0);porphyrin binding site (hatched bar); netropsin binding site (solid bar).
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mation on netropsin affinity for this sequence could be obtained.
The porphyrin cleavage products appeared to be “clean”,
and only one band representing each oligomer was detected.
However, a minor band migrating at position -62 did not
appear to be part of the porphyrin-produced ladder. Since it
also appeared on other autoradiograms involving porphyrin
cleavage of the 139-mer but at a slightly different position,
it was ignored in the present analysis. The autoradiogram
showed 90 and 91 to be two distinct bands but the densitometer
summed the band area for both sites under a single peak
indexed as 91. Sites 157 and 158, in an unresolved portion
of the autoradiogram, were indexed as a single site, 157.
In order to smooth the data for intensity as a function of
netropsin concentration, the sum of all of the band areas except
for the full-length band was obtained for each digest. Plotting
this sum against the total concentration of netropsin present
in the system showed that addition of drug led to an increase
in the amount of cleavage on the 139-mer (Figure 3). On
least-squares fitting the summed areas to polynomial functions
of D,, the total netropsin concentration, we found the quadratic
A(D,) = 92.06

30

1010)D,2 (1)

fit significantly better than the linear function. Cubic and
higher polynominals gave no improvement in fit. To smooth
the data and correct for loading errors and differences in digest
time, each observed site area, ai,was multiplied by the ratio
of A determined from eq 1 to the experimentally determined
value of A for the same value of D,.The correction factors
obtained in this manner were in the range from 0.9 to 1.1.
Inspection of the control band of uncut fragment on the
autoradiogram revealed that a small amount of radioactive
material migrated in the direction of electrophoresis. This
“bleeding” effect was subtracted from the data by scanning
the control lane and determining the appropriate area correction for a particular band on the autoradiogram. This
correction, which was greatest for the site nearest the origin
band site (1 57), was less than 10%of the total area associated
with the cleavage at this site.
RESULTS
From the experiments for zero drug concentration, one can
immediately identify the preferred porphyrin binding regions
to be 46-50, 56-62, 65-67, 85-87, 89-92, 94-96, 98-100,
146-149, and 156-159. These correspond to sequences of at
least three contiguous A or T bases (Figures 1 and 2). The
cleavage pattern for a site can be explained if the bound
porphyrin cuts in the middle of the A-T trimer to which it is
bound. This is true for isolated trimers as well as for trimers
which are part of longer A-T sequences.
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FIGURE 4: Footprinting plots of corrected autoradiographic spot
intensitiesversus total netropsin concentration. The site numbers refer
to the sequence in Figure 2.

As drug is added to the system, three different types of
footprinting plots are observed, as illustrated in Figure 4.
Strong netropsin sites, all of type (A-T),, show rapid decreases
in intensity with increased drug concentration, Figure 4, site
61. The observed decrease represents the direct effect of bound
drug, preventing porphyrin from binding at these sites: the
classic footprinting phenomenon. The positions for which this
occurs are 46-50, 56-62,89-92, and 146-149. Sites of type
(A-T),, 66, 86, 95, 99, and 147, initially show enhanced intensity with added drug as shown in Figure 4, site 66. However, since these sites are weak netropsin binding sites, they
eventually exhibit inhibition of higher drug concentrations.
Enhancements also occur for weaker porphyrin binding sites,
but only for D,in the range from 7.64 to 38.8 pM (see Figure
4, site 73). These sites are all of the type (AsT)(G.C)~or
(A-T)2( G C ) .
In order to consider the change in the porphyrin-DNA
equilibrium as netropsin was added to the system, the amount
of increase in cleavage at the centers of the isolated (A-T),
sites ( 6 6 , 86, 95, 99, and 147) as a function of netropsin
concentration was calculated. For each site we fit the first
nine intensities (for D,I 3.99 pM) to quadratic functions of
drug concentration and divided the slope at D, = 0 by the
intensity at D,= 0 to obtain the relative enhancement. The
results (all times
were 1.39 f 0.59, 0.68 f 0.47, 0.79
f 0.70, 3.3 1 f 1.28, and 1.53 f 0.40. Probable errors were
calculated according to Appendix I found in the supplementary
material.
Inspection of the data revealed that in the concentration
range 0 5 D,I 10.6 pM only the strong drug sites on the
139-mer were accepting netropsin. In calculating binding
constants for the strong sites, the intensity data associated with
15 porphyrin cleavage sites, shown as dots in Figure 2, were
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used in the analysis. (Data for sites 90 and 91 were taken
together, as were data for 157 and 158.) Ten of these sites,
46-50, 56-62, and 89-92, were located within strong netropsin
sites and behaved like site 61, Figure 4. The other five porphyrin sites, all isolated A-T trimers (66, 86,95,99, and 147),
were outside of strong netropsin sites, e.g., site 66, Figure 4.
No weak porphyrin binding sites, e.g., site 73, Figure 4, were
used in the analysis. The eight different drug concentrations
plus two digests carried out in the absence of netropsin give
rise to 150 intensities (concentrations) to be fit by the model.

the drug simultaneously occupy the heptamer if the drug is
bound to (i, i+l, i+2, i+3) while the porphyrin occupies (i+4,
i+5, i+6). An equivalent situation exists for porphyrin occupation of the lowest numbered sites within the heptamer.
Although electrostatic effects would discourage simultaneous
occupations on the same DNA restriction fragment (both the
porphyrin and the drug are cations), it was considered a
possibility in our analysis in order not to introduce additional
parameters to describe the anticooperativity. The fraction of
the first end site which is free of drug is
2

Site Exclusions. We consider how a drug molecule, which
is four nucleotides long, can exclude a porphyrin from its
trinucleotide binding site. For the isolated drug sites of type
(A.T), at positions 89-92 and 156-159 (Figure 2), occupancy
by a netropsin molecule excludes both possible modes of
porphyrin binding to the tetranucleotide sequence. If a netropsin site is a contiguous set of base pairs indexed by ( i , i+ 1,
i+2, i+3), where i is the nucleotide location closest to the label,
porphyrin binding at both ( i , i+l, i+2) and (i+l, i+2, i+3)
is excluded by drug. If the drug binding constant for binding
to ( i , i+l, i+2, i+3) is denoted by Ki
Ki = ci/D0cf

(2)

in which ci is the concentration of sites i at which drug is
bound, cf is the concentration of free sites i, and Do is the
concentration of free drug. The fraction of site i which is
occupied by drug, vi, is then given by
vi

= KiDo/ (1

+ KiD,)

(3)

Since binding of drug to an isolated tetramer blocks both
modes of porphyrin binding to the tetramer, the fraction of
a porphyrin binding site which is free to be occupied by
porphyrin,f, is the same for both i and i+l, i.e.

fi = f i + 1

= 1-

KiDo

1

+ KiD,

(4)

The situation with the A-T pentamer at positions 46-50,
Figure 2, is similar except that drug may occupy two different
positions within the sequence, either of which excludes the
binding of the porphyrin to all three of its binding sites within
the segment. The probability that drug covers the sites from
i to i+3 is KiDo(l KiDo+ Ki+lDo)-l,and the probability that
drug covers the sites from i+l to i+4 is KiclD0(1 + KiDo +
Ki+lDo)-l. Since either situation will prevent the binding of
porphyrin

+

+ KiD, + Ki+1D0)-' Ki+lDo(l + KiD, + Ki+lDo)-l = 1/(1 + KiDo + Ki+lDo)

fi = J;.+1

= f i + 2 = 1 - KiDo(l

(5)

For the A-T heptamer, located at positions 56-62, Figure
2, the situation is more complicated. The size of netropsin on
DNA is -4 base pairs and the size of porphyrin -3 base
pairs, so drug binding to (i+l, i+2, i+3, i+4) or (i+2, i+3,
i+4, i+5) will exclude porphyrin binding to any of its five
possible binding sites within the sequence ( i = 56 here). Since
the probability that no drug is bound to the heptamer is (1
KiDo + Ki+lDo+ Ki+2D0+ Ki+3Do)-1,the fraction of the
three interior binding sites within the heptamer which can bind
porphyrin is

+

3
f;.+l

3

fi = 1 - D,CK,+,(I + D , C K ~ + ~ ) - I

ANALYSISAND MODEL

= f;,+z = f i + 3 = (1

+ DoCKi+1)-'
i=O

(6)

However, it is theoretically possible to have the porphyrin and

i=O

i=O

3

= D&i+3(1

+ DoCKi+1)-'
i=O

(7)

Simi1a r 1y
3

f i + ~= DoKi(1 + DoCKi+I)-'
i=O

(8)

There are no A-T sequences of length greater than seven on
the HindIII/NciI restriction fragment, and the complications
just discussed do not occur for A-T segments of smaller length.
Enhancements. In quantitative experiments involving
DNase I and netropsin (Ward et al., 1988a,b) addition of drug
to the system did not cause a change in the total amount of
cleavage taking place on the 139-mer. This showed that the
equilibrium between the enzyme and DNA was not disturbed
during the footprinting titration and that the enhancements
found in nonbinding regions of the polymer canceled the inhibitions occurring at binding sites. However, the total amount
of cleavage on the fragment is sensitive to the nature of the
carrier DNA. If, for example, the carrier is poly(dAdT).
poly(dAdT), which possesses many more netropsin binding
sites than the 139-mer, addition of drug causes the enzyme
to be displaced from the carrier to the fragment. This gives
rise to an increase in total cleavage similar to that shown in
Figure 3 for MnT4MPyP (Ward and Dabrowiak, unpublished).
The porphyrin cleaves with much higher specificity than
DNase I. Furthermore, a large fraction of its binding sites
are also drug binding sites. If the ratios of drug-blocked
porphyrin sites to free porphyrin sites on the carrier and the
fragment were the same, total cleavage on the fragment would
remain constant as drug is added to the system. As is shown
in Figure 3, this is clearly not the case. Since an increase in
cleavage is observed, drug must be displacing porphyrin from
the carrier to the fragment as the titration proceeds. This can
be easily confirmed by determining the ratio of isolated trinucleotide sites of type (A-T), to longer contiguous tracts of
A and T on both the carrier and the fragment. While an
isolated trimer can bind only porphyrin, the latter type of site
can bind both the drug and MnT4MPyP. From Figure 2, the
ratio between the numbers of these two types of site is 1 for
the fragment while for calf thymus DNA it can be estimated
by assuming this carrier is a random arrangement of A.T and
G.C (see Appendix 2 in the supplementary material), as
-0.67. Thus, addition of drug to the system will result in a
release of porphyrin from the carrier, ultimately causing increased cleavage on the fragment. This mechanism implies
that the change in the porphyrin-DNA equilibrium can be
directly monitored via the cleavage increases at sites of type
(A-T), on the fragment and that the enhancement due to the
effect should be the same at all netropsin binding sites.
The actual enhancements for sites of type (AeT), on the
fragment (initial slope divided by intensity for zero drug), given

-
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in the previous section, are in fact the same within the estimated errors (average value = 1.54 f 0.63). The probable
error in each is as large or larger than the variance, 0.63.
Further, these enhancements are twice that which should result
from drug displacement of porphyrin from only the primary
netropsin sites on the fragment. The enhancement due to such
displacement is calculable from the number of binding sites
on the fragment. Finally, a simple redistribution mechanism,
which was invoked for DNase I (Ward et al., 1988b), would
give no change in total cleavage with added drug, contradicting
eq 1.
Reporting of Site Occupancy by the Cleavage Agent. In
the quantitative footprinting experiment, the change in the
amount of cleavage at a particular site is used to measure the
fraction of that site which is occupied by a drug molecule, vi.
In studies involving DNase I, it is assumed that the cleavage
rate at site i is proportional to 1 - vi or A,, calculated by
equations like 4-8. This assumption yielded reasonable binding
constants for netropsin, lac, and trp repressors toward their
interaction sequences (Brenowitz et al., 1986a,b; Senear, 1986;
Carey, 1988; Ward et al., 1988a).
DNase I, unlike MnT4MpyP, binds and cleaves at nearly
every nucleotide position, so that it acts as if it “sees” a series
of contiguous binding sites. If the barrier height between sites
is less than kT,it is possible for the enzyme to easily transit
in a one-dimensional diffusional process between sites on the
DNA lattice (Winter & von Hippel, 1981). Effectively, it is
not bound to a specific site but rather to the entire fragment.
However, if the probe specificity is high, as is the case with
MnT4MPyP, the barrier height for transiting from a specific
site, e.g., an isolated trimer of type (A.T),, to another site
which binds porphyrin is likely to be high. Then it is appropriate to consider that there is a classic equilibrium between
unbound cleavage agent and agent bound to a site. In this
case, the cleavage at a particular site will not be proportional
to&, as can be shown with a simple example.
Let Ki and Qi represent the binding constants for drug and
probe at a site. Let c be the total concentration of such sites,
P, the total probe concentration, and Db and Pb the concentration of these sites at which drug and probe, respectively,
are bound. The cutting rate is proportional to Pb and vi =
Db/c. The equilibrium expression

is solved to give
pb =

1
-Cfi

2

1
+ -Pt
+ (2Qi)-’ 2

which shows that Pb is not proportional to vi. Expanding the
square root

Thus, Pb will be proportional toA. if P, is large compared to
c and Q;’. This means that, for the footprinting experiment
to report the fraction of binding site unoccupied by drug, the
probe binding constant and the amount of probe must be large
enough to saturate the site with probe. For the experiments
reported here, c and Pt are -50 pM and 1.3 MM,respectively.
On the basis of studies involving related porphyrins, the binding
constant of Mn4MPyP toward calf thymus DNA can be es-
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timated to be -lo7 M-’ (Geacintov, 1987). Thus, for these
experiments, the cutting rate should not be proportional to vi.
We attempted at first to fit the present data using the same
model employed for analyzing the DNase I experiments, but
the fit was less good than in previous work (Ward et al.,
1988a). More important, the values found for the drug binding
constants were all 1-2 orders of magnitude lower than the
values found previously. It is now clear that this is due to the
incorrect assumption that the observed cutting rates by the
porphyrin directly report the fraction of a site which is occupied
by drug. It is clear from eq 10 that this is not so.
Role of the Carrier DNA. The concentration of bound
probe and the concentration of bound drug are determined by
equilibria like eq 9. When carrier DNA is present in excess,
equilibria with carrier sites are more important than equilibria
with sites on the labeled restriction fragment. The equilibria
with carrier sites then determine free drug and free porphyrin
concentrations ( O f and P f ) which, through the equilibria with
fragment sites, determine the bound drug and bound porphyrin
concentrations. For example, the right side of eq 9 would be
written as Pb/[Pf(c- Db - Pb)] and the drug binding equilibrium as

From a model for the carrier, one can determine Pfand D f
by considering similar equilibria.
The increase in cutting rate at A-T trimers on the labeled
fragment, as drug is added, is caused by the drug displacing
the porphyrin from its carrier binding sites to solution. Total
cleavage on the 139-mer Zt(rt) should increase with total drug
concentration initially and level off subsequently, when all
carrier sites which can bind both drug and probe become
saturated with drug. This is reflected in eq 1 by the negative
sign of the quadratic term, which leads to a maximum value
of A of 206.3. When Zt levels off, the free probe concentration
becomes equal to the total probe concentration minus the
concentration of probe bound to sites which can bind probe
but not drug (A-T trimers). The ratio of the amount of
porphyrin bound to fragment when no drug is present to the
amount bound when drug saturates all sites on the carrier is
206.3/92.06 or about 2.3.
The carrier, calf thymus DNA, is considered to consist of
a random arrangement of two kinds of sites, A-T bases and
G-C bases, with a given fraction, p , being A-T bases. We
choosep = 0.6 (Marmur & Doty, 1962) and use probability
theory to calculate the numbers of various kinds of drug and
porphyrin sites present in calf thymus DNA: isolated A-T
trimers, isolated A-T tetramers, etc. (Appendix 2). Given
values for drug and porphyrin binding constants, free drug and
free porphyrin concentrations can be calculated for any total
drug concentration. Note that the carrier serves as a buffer
for both drug and porphyrin, Le., the binding equilibria for
the carrier determine the free porphyrin and free drug concentrations, which in turn determine the amounts of drug and
porphyrin bound to sites on the fragment.
Our model for the carrier shows that a plot of free porphyrin
concentration Pf vs total drug concentration D,is initially
linear, with positive slope, but the slope decreases afterward
and the free porphyrin concentration levels off. This is because
porphyrin continues to bind to A-T trimers, while drug cannot
bind, while other porphyrin sites become saturated with drug.
The free drug concentration Dfalso increases with total drug
concentration, slowly at first and then linearly, after drug
binding sites on the carrier are saturated. Figure 5 shows
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and the same expression describes cutting at i + 4. For cutting
at i 3, the porphyrin must occupy positions i + 2, i 3, and
i 4 and no other porphyrin or drug can then bind, so the
rate is proportional to
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FIGURE 5 :

calculated free porphyrin and free drug concentrations for the
range of total drug concentrations used in the analysis. The
asymptotic behaviors (leveling off of Pf,linear dependence of
Df on 0 , ) are not shown for this range of D,.
The cutting rate at a site will be assumed to be proportional
to the concentration of porphyrin at that site, as calculated
from the appropriate competitive binding equilibrium expression and the free drug and free porphyrin concentrations
Df and Pf. These concentrations, calculated by considering
equilibria with carrier sites, detailed in Appendix 2, depend
on the values of the drug and porphyrin binding constants to
carrier sites. Like the binding constants to fragment sites, the
binding constants to carrier sites will be determined to give
the best fit of calculated to experimental footprinting data.
Cutting Rates. For an isolated A-T trimer, the cutting rate
is proportional to K$f(l + K$f)-'. An A-T tetramer on the
fragment can bind either drug (binding constant Ki) or porphyrin (in two ways), so that the cutting rate at either interior
position is proportional to

xP= KpPf(l + 2K$f

+ KiDf)-'

(12)

There can be no cutting at the end positions according to our
model. An A-T pentamer can bind either drug or porphyrin,
the former in two ways and the latter in three ways, so that
the cutting rate at any of the three interior positions is proportional to

xP = KpPf(l + 3K$f

+ KjDf + Ki+iDf)-'

(13)

Here, Ki and Ki+lare binding constants for the two overlapped
drug binding sites. The constants for the individual sites cannot
be determined according to eq 13.
The heptamer corresponding to A-T's at positions i to i +
6 (i = 56) can bind one or two porphyrins, or a drug molecule
and a porphyrin, and cutting can take place at positions i +
1 to i 5 . Considering all the situations, we find the cutting
rate at i + 1 to be proportional to

+

xp

= [K$f + 4(K$d2 + K$fKi+@fI / [1 + 5KpPf +
6(KppfIz + (Ki+1 + Ki+2 + Kif3 + Ki+dDf +
K$f(Ki+, + Ki+4)Dfl (14)

where Ki+' to Ki+4 are the four drug binding equilibrium
constants associated with drug binding to the heptamer. For
the cutting rate at i + 5, Ki+4and Ki+' are interchanged in
eq 14. Cutting at i + 2 is proportional to
xc

+

/

-5

30

+

= [Kppf + 2(Kppfl2I/[1 + 5K$f + 6(K$d2 + (Ki+l +
Ki+2 + Ki+3 + Ki+4)Df + K$f(Ki+l + Ki+dDfl (15)

According to eq 14-16, the individual values of Ki+2and Ki+,
cannot be determined, but just their sum.
On first attempting to fit experimental intensities with this
model, we found that there were large discrepancies between
the theoretical and experimental points for the highest drug
concentration used, 10.58 pM. With an effective concentration
of primary sites of type (A.T)4present in the system of 10"
M (see Appendix 2), the carrier would be saturated by drug
before Dt = 10.58 pM, causing Df to increase rapidly with Dt.
This would give a sharp decrease in fragment cutting rates
with D,, which was not experimentally observed. Thus, there
are other (weaker) drug binding sites on the carrier which keep
the free drug concentration low at higher values of total drug
concentration. Previous footprinting studies by us (Ward et
al., 1988a) have shown that these weak sites are probably
tetramers including one G or C . To take them into account,
we assume that, in addition to strong binding sites, the carrier
possesses weak drug binding sites at a concentration twice that
of A-T trimers, which are one kind of weak netropsin site. The
netropsin binding constant for these weak sites, K,, is at least
2 orders of magnitude lower than the binding constants for
the strong sites (107-10s M-I). The precise value of K,, as
might be expected, does not significantly affect the determined
values of binding constants for the strong sites; it only helps
improve the fit between calculated and experimental intensities
at a few points (for the highest drug concentration) in the
entire data set.

-

CALCULATION OF BINDINGCONSTANTS
Assuming values for Kp, K,, and Kd and using the statistically determined concentrations of A-T trimers, tetramers,
..., octamers on the carrier, and weak drug sites on the restriction fragment, we can calculate free drug and free porphyrin concentrations for each known total drug concentration
by solving the simultaneous equations for carrier equilibrium
(Appendix 2). The resulting values for free porphyrin and free
drug concentrations, Pf and Df, are used with values for the
Ki to compute the amount of porphyrin bound at each site on
the labeled fragment, and hence the footprinting autoradiographic spot intensities for comparison with experimental intensities. The binding constants for drug molecules on fragment sites are then chosen to minimize the sum of the squared
deviations between experimental and calculated spot intensities.
Initially, the value of the porphyrin binding constant to sites
of type (A-T),, Kp,was chosen as 1 X lo7 M-'. Various values
for Kd (drug binding constant to carrier) were used, as discussed below. In our previous calculation (Ward et al., 1988a),
we assumed a concentration of drug sites on the carrier of 190
pM and determined a binding constant for these sites of 1 X
lo6 M-', which represents an average between the constants
for strong sites and others. Since the strong-site concentration
for the present calculation is 17 pM (see Appendix 2), the
value of Kd should be about 1 . 1 X lo7 M-'. As pointed out
previously, it is the product of Kd and the site concentration
that is important. The total porphyrin concentration Pt,
measured optically, was 1.3 pM in all the experiments considered here, while Dt, the total netropsin concentration, varied
from 0 to about 10 pM.
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Table I: Netropsin Binding Constants (X10-7 M)"
nucleotide
sequence
positionb
of site
MnT4MPyP
DNase IC
46 47
7.8
9
8d
7TAA
0.3
0.2d
MTT
0.4
56
18
20d
26
57 + 58
AATT
59
lTM
1.4
13
7d
AAAT
89
n-TA
5.3
14
1Od
156
2.1
8
Id
"Values were determined with Kd = 3.5 X lo7 M-I, Kp = 1.0 X IO7
M-I, and K, = 1.0 X IO6 M-I. bTheposition of the lowest numbered
nucleotide of the tetramer binding site is given, see Figure 2. cData
from Ward et al. (1988a). dCarrier-free experiment.
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FIGURE 8:

Experimental ( 0 )and calculated (0)footprinting plots
for various binding and enhancement sites on the 139-mer. Kp = 1
X IO' M-I; Kd = 3.5 X lo7 M-'; K, = 1.0 X lo6 M-'.
FIGURE 7:

The site binding constants for drug on the fragment are
determined by searching, using the simplex search algorithm
(Fletcher, 1980), for the set which minimizes the sum of the
squared deviations between the experimental and calculated
spot intensities. For any set of values for Kd, Kp,and K , the
algorithm converges properly to yield the set of Ki which
minimizes:

D = CCCZjj - l j j ) 2
i

j

(17)

where Zii is the experimental intensity for site i at thejth total
drug concentration and is the corresponding calculated value.
The resulting mean-square deviation, D,is smaller than what
we obtained with the earlier study involving DNase I as a
footprinting probe (Ward et al., 1988a). Due to the sizes of
the porphyrin and the drug when bound to DNA, the cutting-rate expressions do not allow the determination of all Ki,
but only K46 + K47, KS6, K57 + K S SK
, s ~Ka9,
, and K156.

I

C D R U G 3 ,UM

1

e

II

See caption for Figure 7.

Figure 6 is a plot of the lowest value of D found for various
choices of Kd, the netropsin binding constant to the carrier.
It is seen that there is a clear minimum for Kd 3.5 X lo7
M-'. The value of Kd is thus determined, like the values of
Ki, by minimization of D in eq 17. In Table I, we give the
Ki values corresponding to this minimum and compare them
with the values found by analysis of DNase I footprinting data.
The experimental intensities are compared with the calculated
ones for the "best fit" in Figures 7 and 8 (Ward et al., 1988a).
As is evident from Table I, the netropsin binding constants
obtained with DNase I and MnT4MPyP are in the same rank
order and are in generally good agreement with regard to
magnitude. The site with the lowest binding constant, 56,
contains the sequence 5'-TA-3' which is expected to produce
a distortion in the minor groove of DNA (Calladine, 1982).
Although further study will be necessary, this distortion likely
produces less than optimum drug-DNA contacts, leading to
a decrease in the binding constant of netropsin. Agreement
between the DNase I and MnT4MPyP data appears poorest
for site 59. Since this site is in a heavily overlapped region
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(Appendix 2, eq 11) involves only the product Kff, so doubling
the assumed value of Kp simply divides all of the calculated
values of Pf by 2. The same Kp is used for the fragment as
for the carrier, and only K T f enters eq 12-16. Thus, if Kp
> -lo6 M-l, it is unimportant to know its exact value in
calculating valid binding constants for the drug bound to its
interaction sequences.
CONCLUSIONS
In this paper we have examined the ability of the AT-specific
cleaving agent MnT4MPyP to report valid binding information
for netropsin bound to a 139 base pair restriction fragment
of pBR-322 DNA. The reporting of site occupancy by the
porphyrin is different from that of DNase I. The behavior
of the latter may be understood by considering that DNase
I “sees” a closely spaced collection of sites on DNA with
comparable binding constants. The potential surface involves
closely spaced minima, so the barrier to movement from one
site to its neighbor cannot be very large and the enzyme can
be thought of as being bound to the fragment as a whole rather
than to a specific site on the fragment. On the other hand,
the porphyrin complex “sees” a few well-separated minima,
so that it is appropriate to consider binding equilibria for
individual sites on the fragment. As we have shown, analysis
of the porphyrin data using the model developed for DNase
I leads to equilibrium constants for netropsin which are several
orders of magnitude lower than those previously determined
(Ward et al., 1988a). The redistribution model employed for
DNase I is also incapable of explaining the increase in the total
amount of cleavage on the fragment with added drug, or the
magnitude of the drug-induced enhancement in cutting rate
at sites where netropsin cannot bind. These are explained
naturally in the model presented above, which considers

competitive binding of drug and porphyrin at specific sites on
both the fragment and carrier DNA present. Analysis according to this model also yields site-specific binding constants
for netropsin in good agreement with previously determined
values.
While the high specificity of MnT4MPyP prevents it from
being a “broad spectrum” footprinting probe useful for studying ligands of unknown specificity, it can be used to measure
binding constants for drugs with affinities for AT sites. In
this respect it is similar to the AT-specific compound Cu(ophen)* which has been used in footprinting experiments involving netropsin and the duplex d(CGCGAATTCGCG)*
(Kuwabara et al., 1986). From the present study and earlier
published experimental (Ward et al., 1988a) and theoretical
work (Goodisman & Dabrowiak, 1985), it is clear that the
detailed mechanism by which the probe binds and cleaves
DNA is unimportant for reporting valid binding information
for the drug. While DNase I catalyzes a phosphodiester hydrolysis of the DNA backbone, the porphyrin cleaves DNA
via an oxo intermediate which appears to attack the deoxyribose moiety of the polymer. It is the specificity of the probe
and not its mechanism of binding or cutting, per se, which
needs to be addressed in obtaining information on site occupancy in the quantitative experiment. This point has recently
been reinforced by preliminary results of quantitative footprinting experiments involving Fe-MPE (Dabrowiak and
Goodisman, unpublished results). This intercalating complex
cleaves DNA via radical release but, like DNase I, exhibits
relatively low DNA sequence specificity. Despite the dramatic
differences in cleavage mechanism, both the enzyme and
Fe-MPE can be analyzed with the DNase I type redistribution
model to yield valid binding constants for ligands bound to
DNA.
When carrier DNA is present in excess, as is the case for
the results considered here, it serves as a buffer for both drug
and probe. While its presence in the experiment was initially
viewed as a complication, it allows the determination of netropsin binding constants, K,, without direct knowledge of the
parameter Kp, the porphyrin binding constant toward its interaction sequences. The values of the Ki as well as the
mean-square deviation D (Figure 9) are independent of Kpfor
Kp > lo6 M-’.
As before (Ward et al., 1988a), the binding of drug to DNA
was assumed to occur in an independent noncooperative
fashion. This assumption was included in the model used for
analysis for two reasons. First, netropsin is a groove-binding
drug, and unlike intercalators, it binds without greatly distorting DNA. Without distortion the possibility that affinities
for adjacent binding sites would be altered through allosteric
effects was considered remote. Also, only the early loading
events on the polymer were used in the analysis. Thus, although many strong netropsin sites are present on the 139-mer,
only a relatively small fraction of the fragments present in the
reaction medium possess more than one bound drug molecule
in the concentration range studied.
Although the porphyrin concentration used in the work was
relatively low, about one porphyrin per fragment, the possibility
exists that porphyrins bound to nearby drug sites would influence the binding constant of the drug for those sites.
However, the generally good agreement between binding
constants derived from DNase I and MnT4MPyP, which have
radically different binding mechanisms, suggests that the
porphyrindrug cooperative effects are probably small and not
detectable with the present data. A possible exception may
be the site at 89 which is flanked by two porphyrin binding
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sites. Occupancy of these flanking sites by MnT4MPyP may
produce a distortion within the netropsin site causing the
binding constant for this site to be lower than that obtained
with DNase I, Table I.
The method described in this paper utilizes only the autoradiographic spot intensities derived from footprinting experiments and certain easily measured concentrations to determine drug binding constants as a function of sequence on
natural DNA. The success of the approach depends on collecting intensity data for many sites on a DNA polymer. Since
the number of experimental points is much larger than the
number of parameters (binding constants) characterizing the
loading events, a minimization approach can be used to calculate individual-site binding constants for ligands. Although
the full scope and limitations of quantitative footprinting are
yet to be defined, the method is clearly superior to conventional
techniques which yield average rather than site-specific isotherms for ligand binding to a DNA lattice.
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SUPPLEMENTARY
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Appendixes 1 and 2 discussing errors in quadratic fits and
the analysis of the equilibrium involving the carrier DNA (7
pages). Ordering information is given on any current masthead
page.
Registry No. MnT4MPyP, 70649-54-6; netropsin, 1438-30-8.
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